Reference health
Bioactive Macrocycles from Nature
159/159 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
23 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 159 checked references that resolve
resolves10.1021/jm400887j
Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?
resolves10.1038/nrd2590
The exploration of macrocycles for drug discovery — an underexploited structural class
resolves10.1021/jm1012374
Macrocycles Are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocycles in Drug Discovery
resolves10.3181/00379727-45-11768
Bacteriostatic and Bactericidal Substances Produced by a Soil Actinomyces.
resolves10.1007/BF00524717
Experimentelle Untersuchungen �ber die Wirkung von Actinomycin C (HBF 386) bei b�sartigen Geschw�lsten
resolves10.1007/BF00524710
Erfahrungen mit neuen cytostatischen Mitteln bei H�moblastosen und Carcinomen und die Abgrenzung ihrer Wirkungen gegen R�ntgentherapie
resolves10.1021/bi9006836
Novel Molecular Mechanism for Actinomycin D Activity as an Oncogenic Promoter G-Quadruplex Binder
resolves10.1016/S0021-9258(18)97578-2
The Biosynthesis and Metabolism of Erythromycins by Streptomyces erythreus
resolves10.1021/ja304682q
Precursor Directed Biosynthesis of an Orthogonally Functional Erythromycin Analogue: Selectivity in the Ribosome Macrolide Binding Pocket
resolves10.2174/092986709787315559
Bacterial RNA Polymerase Inhibitors: An Organized Overview of their Structure, Derivatives, Biological Activity and Current Clinical Development Status
resolves10.5588/ijtld.12.0083
The chemotherapy of tuberculosis: past, present and future [State of the art]
resolves10.2217/fmb.12.75
Repurposing Screens Identify Rifamycins as Potential Broad-Spectrum Therapy for Multidrug-Resistant
<i>Acinetobacter baumannii</i>
and Select Agent Microorganisms
resolves10.1002/anie.201302749
Anthracimycin, a Potent Anthrax Antibiotic from a Marine‐Derived Actinomycete
resolves10.1358/dof.2010.35.6.1497487
Antibody-maytansinoid conjugates: A new strategy for the treatment
of cancer
resolves10.1358/dof.2011.36.11.1711891
Trastuzumab emtansine, tumor-activated prodrug (TAP)
immunoconjungate, oncolytic
resolves10.2119/molmed.2012.00302
Trastuzumab-DM1: A Clinical Update of the Novel Antibody-Drug Conjugate for HER2-Overexpressing Breast Cancer
resolves10.1099/ijs.0.64660-0
Burkholderia rhizoxinica sp. nov. and Burkholderia endofungorum sp. nov., bacterial endosymbionts of the plant-pathogenic fungus Rhizopus microsporus
resolves10.1002/anie.201300576
Total Synthesis of the Tubulin Inhibitor WF‐1360F Based on Macrocycle Formation through Ring‐Closing Alkyne Metathesis
resolves10.3987/COM-12-12613
Preparation of a Diverse Purine-Scaffold Library via One-Step Palladium Catalyzed Cross-Coupling
resolves10.1016/0042-6822(88)90649-6
Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A
resolves10.1073/pnas.91.18.8324
Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.
resolves10.1016/S0092-8674(00)80203-2
Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent
resolves10.1021/jm8006068
Optimizing Natural Products by Biosynthetic Engineering: Discovery of Nonquinone Hsp90 Inhibitors
resolves10.1038/ja.2011.24
New non-quinone geldanamycin analogs from genetically engineered Streptomyces hygroscopicus
resolves10.1002/asia.200900634
New Approaches to the Total Synthesis of the Bryostatin Antitumor Macrolides
resolves10.1021/np040007k
Structure of Bryostatin 20: A Symbiont-Produced Chemical Defense for Larvae of the Host Bryozoan, <i>Bugula </i><i>n</i><i>eritina</i>
resolves10.1351/pac198860111587
Asymmetric synthesis and its applications: towards the synthesis of bryostatin 1
resolves10.1002/(SICI)1521-3773(19980918)37:17<2354::AID-ANIE2354>3.0.CO;2-9
Asymmetric Synthesis of Bryostatin 2
resolves10.1002/1521-3773(20000703)39:13<2290::AID-ANIE2290>3.0.CO;2-6
Total Synthesis of Bryostatin 3
resolves10.1246/bcsj.77.875
Evolution of Synthetic Strategies for Highly Functionalized Natural Products: A Successful Route to Bryostatin 3
resolves10.1021/ol061626i
Enantioselective Formal Total Synthesis of the Antitumor Macrolide Bryostatin 7
resolves10.1038/nature07543
Total synthesis of bryostatin 16 using atom-economical and chemoselective approaches
resolves10.1002/chem.201002930
Atom‐Economic and Stereoselective Syntheses of the Ring A and B Subunits of the Bryostatins
resolves10.1002/chem.201002932
Total Syntheses of Bryostatins: Synthesis of Two Ring‐Expanded Bryostatin Analogues and the Development of a New‐Generation Strategy to Access the C7–C27 Fragment
resolves10.1021/ja8022169
Convergent Assembly of Highly Potent Analogues of Bryostatin 1 via Pyran Annulation: Bryostatin Look-Alikes That Mimic Phorbol Ester Function
resolves10.1021/ja105129p
Total Synthesis of Bryostatin 16 Using a Pd-Catalyzed Diyne Coupling as Macrocyclization Method and Synthesis of C20-<i>epi</i>-Bryostatin 7 as a Potent Anticancer Agent
resolves10.1073/pnas.1015270108
Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity
resolves10.1016/j.tet.2011.09.058
Function oriented synthesis: preparation and initial biological evaluation of new A-ring-modified bryologs
resolves10.1021/cb300671s
Biological Profile of the Less Lipophilic and Synthetically More Accessible Bryostatin 7 Closely Resembles That of Bryostatin 1
resolves10.1038/nchem.1395
Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro
resolves10.1126/science.287.5453.640
Cloning and Heterologous Expression of the Epothilone Gene Cluster
resolves10.1016/S1074-5521(00)00075-2
The biosynthetic gene cluster for the microtubule-stabilizing agents epothilones A and B from Sorangium cellulosum So ce90
resolves10.1128/AAC.46.9.2772-2778.2002
Heterologous Expression of Epothilone Biosynthetic Genes in
<i>Myxococcus xanthus</i>
resolves10.1002/bit.10202
Optimizing the heterologous production of epothilone D in <i>Myxococcus xanthus</i>
resolves10.1021/np030218+
Isolation and Characterization of New Epothilone Analogues from Recombinant <i>Myxococcus </i><i>x</i><i>anthus </i>Fermentations
resolves10.1007/s00253-003-1263-1
Nutrient regulation of epothilone biosynthesis in heterologous and native production strains
resolves10.1016/j.jbiotec.2003.07.015
Myxobacteria: proficient producers of novel natural products with various biological activities—past and future biotechnological aspects with the focus on the genus Sorangium
resolves10.1039/b817073h
The impact of genomics on the exploitation of the myxobacterial secondary metabolome
resolves10.7164/antibiotics.31.539
Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation.
resolves10.7164/antibiotics.28.727
Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.
resolves10.7164/antibiotics.28.721
Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.
resolves10.1126/science.1715094
Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast
resolves10.1038/ja.2011.61
Identification of novel rapamycin derivatives as low-level impurities in active pharmaceutical ingredients
resolves10.1073/pnas.0710424105
Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities
resolves10.1351/PAC-CON-11-11-09
Targeting neurodegenerative diseases: Drug discovery in a challenging arena
resolves10.1096/fj.06-7667com
The immunophilin FKBP52 specifically binds to tubulin and prevents microtubule formation
resolves10.1073/pnas.1105160108
Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells
resolves10.1093/hmg/ddm294
A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin
resolves10.1016/j.copbio.2006.09.006
Therapeutic potential of natural product signal transduction agents
resolves10.1021/jm0704090
Natural Products as Leads to Potential Drugs: An Old Process or the New Hope for Drug Discovery?
resolves10.1021/np50073a015
Incorporation of Acetate, Propionate, and Methionine into Rapamycin by Streptomyces hygroscopicus
resolves10.1073/pnas.1015773108
Biosynthesis of the immunosuppressants FK506, FK520, and rapamycin involves a previously undescribed family of enzymes acting on chorismate
resolves10.1039/b804602f
Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs
resolves10.1038/ja.2010.71
Biosynthesis of rapamycin and its regulation: past achievements and recent progress
resolves10.1038/nature12051
High-level semi-synthetic production of the potent antimalarial artemisinin
resolves10.1016/j.ymben.2012.11.001
Recombinant strains for the enhanced production of bioengineered rapalogs
resolves10.1039/C2SC21833J
Structure guided design of improved anti-proliferative rapalogs through biosynthetic medicinal chemistry
resolves10.1021/cb3005325
Revealing Nature’s Synthetic Potential Through the Study of Ribosomal Natural Product Biosynthesis
resolves10.1016/j.bmc.2012.08.038
‘Inverted’ analogs of the antibiotic gramicidin S with an improved biological profile
resolves10.1016/j.pain.2011.10.002
Intrathecal combination of ziconotide and morphine for refractory cancer pain: A rapidly acting and effective choice
resolves10.1021/bi00382a004
Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using .omega.-conotoxin from Conus magus venom
resolves10.1016/j.toxicon.2010.12.003
Cyclization of conotoxins to improve their biopharmaceutical properties
resolves10.1002/anie.201000620
The Engineering of an Orally Active Conotoxin for the Treatment of Neuropathic Pain
resolves10.7164/antibiotics.43.1524
Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents.
resolves10.1016/S0021-9258(18)41547-5
Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase.
resolves10.1073/pnas.93.23.13143
Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase
resolves10.1016/0040-4039(96)01844-8
Apicidins: Novel cyclic tetrapeptides as coccidiostats and antimalarial agents from Fusarium pallidoroseum
resolves10.1002/anie.200602047
Azumamides A–E: Histone Deacetylase Inhibitory Cyclic Tetrapeptides from the Marine Sponge <i>Mycale izuensis</i>
resolves10.1021/ol070046y
Total Synthesis of Azumamide A and Azumamide E, Evaluation as Histone Deacetylase Inhibitors, and Design of a More Potent Analogue
resolves10.1021/jm4008449
Total Synthesis and Full Histone Deacetylase Inhibitory Profiling of Azumamides A–E as Well as β<sup>2</sup>- <i>epi</i>-Azumamide E and β<sup>3</sup>-<i>epi</i>-Azumamide E
resolves10.7164/antibiotics.47.301
FR901228, a novel antitumor bicyclic depsipeptide produced by chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity.
resolves10.1006/excr.1998.4027
FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor
resolves10.1021/ja039258q
Total Synthesis of Spiruchostatin A, a Potent Histone Deacetylase Inhibitor
resolves10.1016/j.bcp.2008.06.004
Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A
resolves10.3892/ijo.2013.2042
A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma
resolves10.1021/ol202197q
Total Synthesis and Stereochemical Assignment of Burkholdac B, a Depsipeptide HDAC Inhibitor
resolves10.1186/1757-2215-5-12
Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy
resolves10.1021/ja7110064
Structure and Activity of Largazole, a Potent Antiproliferative Agent from the Floridian Marine Cyanobacterium <i>Symploca</i> sp.
resolves10.1021/ja8013727
Total Synthesis and Molecular Target of Largazole, a Histone Deacetylase Inhibitor
resolves10.1021/ol8014623
Enantioselective Total Synthesis of (+)-Largazole, a Potent Inhibitor of Histone Deacetylase
resolves10.1021/ol8013478
A Concise Total Synthesis of Largazole, Solution Structure, and Some Preliminary Structure Activity Relationships
resolves10.1021/ol801532s
Synthesis and Activity of Largazole Analogues with Linker and Macrocycle Modification
resolves10.1021/ja8033763
Total Synthesis and Biological Mode of Action of Largazole: A Potent Class I Histone Deacetylase Inhibitor
resolves10.1021/ol100308a
Total Synthesis and Biological Evaluation of Largazole and Derivatives with Promising Selectivity for Cancers Cells
resolves10.1021/jm100244y
Synthesis and Biological Characterization of the Histone Deacetylase Inhibitor Largazole and C7- Modified Analogues
resolves10.1016/j.bmc.2011.02.024
Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability
resolves10.1016/j.bmcl.2013.06.012
Synthesis and HDAC inhibitory activity of isosteric thiazoline-oxazole largazole analogs
resolves10.1182/blood-2011-06-362434
Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents
resolves10.1021/ml400093y
Largazole Arrests Cell Cycle at G1 Phase and Triggers Proteasomal Degradation of E2F1 in Lung Cancer Cells
resolves10.1111/liv.12034
A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor‐β and vascular endothelial growth factor signalling
resolves10.1021/jm900850t
Discovery of Potent and Selective Histone Deacetylase Inhibitors via Focused Combinatorial Libraries of Cyclic α<sub>3</sub>β-Tetrapeptides
resolves10.1021/jm101092u
Non-Natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity
resolves10.3390/molecules18021337
Case Studies of the Synthesis of Bioactive Cyclodepsipeptide Natural Products
resolves10.2174/0929867311320140006
Peptide Based Macrocycles: Selective Histone Deacetylase Inhibitors with Antiproliferative Activity
resolves10.1126/science.283.5403.854
Mycolactone: A Polyketide Toxin from
<i>Mycobacterium ulcerans</i>
Required for Virulence
resolves10.1002/chem.201102542
A Diverted Total Synthesis of Mycolactone Analogues: An Insight into Buruli Ulcer Toxins
resolves10.1371/journal.pntd.0002143
Structure-Activity Relationship Studies on the Macrolide Exotoxin Mycolactone of Mycobacterium ulcerans
resolves10.1016/j.bmcl.2011.01.111
Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility
resolves10.1016/j.bmcl.2011.01.097
Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo
resolves10.1016/j.bmcl.2011.01.096
Novel second generation analogs of eribulin. Part III: Blood–brain barrier permeability and in vivo activity in a brain tumor model
resolves10.1016/j.bbrc.2003.09.029
A novel macrocyclic tetrapeptide mimetic that exhibits low-picomolar Grb2 SH2 domain-binding affinity
resolves10.1021/jm030510e
Macrocyclization in the Design of Non-Phosphorus-Containing Grb2 SH2 Domain-Binding Ligands
resolves10.1016/j.bmcl.2011.05.102
Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model
resolves10.1021/cr030101q
Bacterial Topoisomerase Inhibitors: Quinolone and Pyridone Antibacterial Agents
The 23 references without a DOI — listed, not checked
no DOI — not checkedAnticancer Agents from Natural Products
no DOI — not checkedAnticancer Agents from Natural Products
no DOI — not checked2023052000560418900_BK9781849737012-00001-cit35
no DOI — not checkedAnticancer Agents from Natural Products
no DOI — not checked2023052000560418900_BK9781849737012-00001-cit40
no DOI — not checkedAnticancer Agents from Natural Products
no DOI — not checked2023052000560418900_BK9781849737012-00001-cit42
no DOI — not checkedBioorganic Marine Chemistry
no DOI — not checkedProgress in the Chemistry of Organic Natural Products
no DOI — not checkedBryozoans in Space and Time
no DOI — not checkedAnticancer Drug Development
no DOI — not checked2023052000560418900_BK9781849737012-00001-cit56
no DOI — not checked2023052000560418900_BK9781849737012-00001-cit57
no DOI — not checkedAnticancer Agents from Natural Products
no DOI — not checkedAnticancer Agents from Natural Products
no DOI — not checkedAnticancer Agents from Natural Products
no DOI — not checked2023052000560418900_BK9781849737012-00001-cit83
no DOI — not checked2023052000560418900_BK9781849737012-00001-cit115
no DOI — not checked2023052000560418900_BK9781849737012-00001-cit117
no DOI — not checked2023052000560418900_BK9781849737012-00001-cit127
no DOI — not checkedNatural Products and Cancer Drug Discovery
no DOI — not checked2023052000560418900_BK9781849737012-00001-cit143
no DOI — not checkedAnticancer Agents from Natural Products
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1039/9781782623113-00001"><img src="https://citestamp.com/citestamped/10.1039/9781782623113-00001/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1039/9781782623113-00001)